프로테아제

Effects of a multi-strain Bacillus spp. direct-fed microbial and a protease enzyme on growth performance, nutrient digestibility, blood characteristics, fecal microbiota, and noxious gas emissions of grower pigs fed corn-soybean-meal-based diets-A meta-analysis.

1. J Anim Sci. 2017 Sep;95(9):4018-4029. doi: 10.2527/jas2017.1522. Effects of a multi-strain Bacillus spp. direct-fed microbial and a protease enzyme on growth performance, nutrient digestibility, blood characteristics, fecal microbiota, and noxious gas emissions of grower pigs fed corn-soybean

Growth reconstitution following antiretroviral therapy and nutritional supplementation: systematic review and meta-analysis.

2. AIDS. 2015 Sep 24;29(15):2009-23. doi: 10.1097/QAD.0000000000000783. Growth reconstitution following antiretroviral therapy and nutritional supplementation: systematic review and meta-analysis. McGrath CJ(1), Diener L, Richardson BA, Peacock-Chambers E, John-Stewart GC. Author information: (1

A Phase 1 Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study of DISC-3405, a Novel Recombinant Humanized Monoclonal Antibody Targeting TMPRSS6, in Adult Healthy Volunteers.

3. J Clin Pharmacol. 2026 May;66(5):e70199. doi: 10.1002/jcph.70199. A Phase 1 Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study of DISC-3405, a Novel Recombinant Humanized Monoclonal Antibody Targeting TMPRSS6, in Adult Healthy Volunteers. Liu G(1), Howell H(

A randomized phase II trial of gemcitabine, nab-paclitaxel, cisplatin with or without a medically supervised ketogenic diet for patients with metastatic pancreatic cancer.

4. Cancer. 2026 Mar 15;132(6):e70343. doi: 10.1002/cncr.70343. A randomized phase II trial of gemcitabine, nab-paclitaxel, cisplatin with or without a medically supervised ketogenic diet for patients with metastatic pancreatic cancer. Jameson GS(1), Roe DJ(2), Borazanci E(1)(3), Hanna DL(4), Rob

HIV drug resistance amongst children and adolescents with viraemia in Lesotho and Tanzania: a nested analysis in the GIVE MOVE trial.

5. J Antimicrob Chemother. 2026 Mar 4;81(4):dkag070. doi: 10.1093/jac/dkag070. HIV drug resistance amongst children and adolescents with viraemia in Lesotho and Tanzania: a nested analysis in the GIVE MOVE trial. Schönenberger CM(1)(2), Haenggi K(1)(2), Ringera IK(1)(2)(3), Luoga E(4)(5), Bresse

Low-Molecular-Weight Collagen Peptide Supplementation Improves Cellulite Severity, Skin Elasticity, and Hair Shaft Diameter: A Clinical Study with Pharmacokinetic Evaluation.

6. J Med Food. 2026 Apr;29(4):187-195. doi: 10.1177/1096620X261428336. Epub 2026 Mar 6. Low-Molecular-Weight Collagen Peptide Supplementation Improves Cellulite Severity, Skin Elasticity, and Hair Shaft Diameter: A Clinical Study with Pharmacokinetic Evaluation. Hwang S(1), Won J(2), Kim S(1),

Randomised, phase 1 evaluation of the safety, tolerability, pharmacokinetics and pharmacodynamics of iptacopan in healthy volunteers.

7. Br J Pharmacol. 2026 Jun;183(11):2874-2889. doi: 10.1111/bph.70339. Epub 2026 Feb 17. Randomised, phase 1 evaluation of the safety, tolerability, pharmacokinetics and pharmacodynamics of iptacopan in healthy volunteers. Baltcheva I(1), Junge G(1), Kulmatycki K(2)(3), Schmouder R(4), Schubart

Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial.

8. Lancet. 2026 Feb 7;407(10528):599-610. doi: 10.1016/S0140-6736(25)01945-2. Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-labe

Weight gain, body composition, and metabolic parameters of dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: an ancillary analysis of the ODYSSEY trial.

9. Lancet Child Adolesc Health. 2026 Mar;10(3):189-202. doi: 10.1016/S2352-4642(25)00339-6. Epub 2026 Jan 21. Weight gain, body composition, and metabolic parameters of dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: an ancillary analysis of the ODY

First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP1617, a Cathepsin-S Inhibitor, in Healthy Adult Subjects.

10. Clin Transl Sci. 2026 Feb;19(2):e70460. doi: 10.1111/cts.70460. First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP1617, a Cathepsin-S Inhibitor, in Healthy Adult Subjects. Kojima T(1), Chen W(2), Smulders R(2), Stanhope S(2), Kowalski D(2)

Integrase versus protease inhibitor therapy in advanced HIV disease (LAPTOP): a multicountry, randomised, open-label, non-inferiority trial.

11. Lancet Infect Dis. 2026 May;26(5):510-521. doi: 10.1016/S1473-3099(25)00681-4. Epub 2025 Dec 1. Integrase versus protease inhibitor therapy in advanced HIV disease (LAPTOP): a multicountry, randomised, open-label, non-inferiority trial. Behrens GMN(1), Assoumou L(2), Liegeon G(3), Antinori A

Partially Replacing Dietary Carbohydrate With Unsaturated Fat or Protein Shifts Protein-Based HDL Subspecies Toward Lower Coronary Heart Disease Risk.

12. Arterioscler Thromb Vasc Biol. 2026 Jan;46(1):251-267. doi: 10.1161/ATVBAHA.125.323709. Epub 2025 Dec 2. Partially Replacing Dietary Carbohydrate With Unsaturated Fat or Protein Shifts Protein-Based HDL Subspecies Toward Lower Coronary Heart Disease Risk. Zhang B(#)(1)(2)(3), Furtado JD(#)(1

Tumor-targeted Exosomal Delivery of Celastrol for Enhanced Therapeutic Efficacy in NSCLC.

13. Theranostics. 2026 Mar 3;16(10):5125-5149. doi: 10.7150/thno.125096. eCollection 2026. Tumor-targeted Exosomal Delivery of Celastrol for Enhanced Therapeutic Efficacy in NSCLC. Moholkar DN(1)(2), Kandimalla R(1)(2), Saeed M(3), Arif Y(1), Tyagi N(1), Singhal R(4)(5), Kyakulaga AH(1)(2), Sae

Synergistic Action of Alpha-cypermethrin, Propolis Nanoemulsions and Other Activator Adjuvants for Peach Fruit Fly, Bactrcera zonata Management.

14. Neotrop Entomol. 2026 Apr 15;55(1):29. doi: 10.1007/s13744-026-01377-8. Synergistic Action of Alpha-cypermethrin, Propolis Nanoemulsions and Other Activator Adjuvants for Peach Fruit Fly, Bactrcera zonata Management. Romeh AA(1), El-Nagar HM(2), Romeh ZAA(1), Ismail AM(3), Al-Kahtani SN(4),

Synthesis of New Asymmetrical Chalcones and Evaluation of Their Use in Combination with Curcumin Against Rhodesain of T. brucei rhodesiense.

15. Int J Mol Sci. 2026 Apr 7;27(7):3320. doi: 10.3390/ijms27073320. Synthesis of New Asymmetrical Chalcones and Evaluation of Their Use in Combination with Curcumin Against Rhodesain of T. brucei rhodesiense. Di Chio C(1), Starvaggi J(1), Natale B(2), Previti S(1), De Luca F(1), Cosconati S(2),

Optimizing Tacrolimus Target Trough Levels in Organ Transplantation Among Patients Living With HIV Receiving Antiretroviral Therapy.

31. Clin Transplant. 2026 Apr;40(4):e70538. doi: 10.1111/ctr.70538. Optimizing Tacrolimus Target Trough Levels in Organ Transplantation Among Patients Living With HIV Receiving Antiretroviral Therapy. Akanit U(1)(2). Author information: (1)Department of Pharmacy Practice, Faculty of Pharmaceutic

Potent in vitro synergistic antiviral effects of the pan-coronavirus fusion inhibitor EK1 in combination with RBD-specific antibodies or M(pro) inhibitors.

32. J Virol. 2026 Apr 21;100(4):e0007626. doi: 10.1128/jvi.00076-26. Epub 2026 Mar 30. Potent in vitro synergistic antiviral effects of the pan-coronavirus fusion inhibitor EK1 in combination with RBD-specific antibodies or M(pro) inhibitors. Xiu R(1), Wang Y(1), Cai W(2), Wang Q(1), Xie M(1), W

MG-101, a cysteine protease inhibitor identified through high-throughput screening, exhibits in vivo efficacy and synergy with remdesivir against SARS-CoV-2.

34. Biomed Pharmacother. 2026 Mar;196:119076. doi: 10.1016/j.biopha.2026.119076. Epub 2026 Feb 2. MG-101, a cysteine protease inhibitor identified through high-throughput screening, exhibits in vivo efficacy and synergy with remdesivir against SARS-CoV-2. Heo J(1), Park S(1), Lee H(1), Jeon Y(1

HIV-associated drug-resistant TB: expanded treatment options and emerging threats.

15. Curr Opin HIV AIDS. 2026 Mar 1;21(2):172-179. doi: 10.1097/COH.0000000000001003. Epub 2025 Dec 29. HIV-associated drug-resistant TB: expanded treatment options and emerging threats. Abadie M(1)(2), Kay A(1)(2). Author information: (1)Baylor College of Medicine, Houston, Texas, USA. (2)Baylo

Targeting uPARAP with an Antibody-Drug Conjugate Exhibits Efficacy against Mesothelioma and Synergizes with Cisplatin.

49. Cancer Res Commun. 2026 Jan 1;6(1):130-142. doi: 10.1158/2767-9764.CRC-25-0381. Targeting uPARAP with an Antibody-Drug Conjugate Exhibits Efficacy against Mesothelioma and Synergizes with Cisplatin. Çakılkaya P(1), Egeland Larsen IM(1), Jiang Q(2), Sandal Nørregaard K(1), Gårdsvoll H(1), Zha

Synergistic effects of Calebin A and docetaxel on apoptosis and migration in prostate cancer cells.

43. Daru. 2025 Nov 27;34(1):3. doi: 10.1007/s40199-025-00579-6. Synergistic effects of Calebin A and docetaxel on apoptosis and migration in prostate cancer cells. Faal MA(#)(1), Tasbandi T(#)(1), Aliyari M(1), Shojaei M(1), Eskandari M(1), Sahebkar A(2)(3)(4), Hosseini H(5), Jalili-Nik M(6). A

Pharmacokinetic and mass balance characterization of [(14)C] RAY1216, a SARS-CoV-2 M(pro) inhibitor, in healthy Chinese male subjects.

3. Antivir Ther. 2025 Oct;30(5):13596535251377204. doi: 10.1177/13596535251377204. Epub 2025 Sep 10. Pharmacokinetic and mass balance characterization of [(14)C] RAY1216, a SARS-CoV-2 M(pro) inhibitor, in healthy Chinese male subjects. Hu W(1)(2), Ding J(2)(3), Xie Y(1)(2), Zhang T(1)(2), Peng Y

Effects of antiretrovirals on major adverse cardiovascular events in the REPRIEVE trial: a longitudinal cohort analysis.

30. Lancet HIV. 2025 Jul;12(7):e496-e505. doi: 10.1016/S2352-3018(25)00043-8. Epub 2025 Jun 4. Effects of antiretrovirals on major adverse cardiovascular events in the REPRIEVE trial: a longitudinal cohort analysis. Fichtenbaum CJ(1), Malvestutto CD(2), Watanabe MG(3), Davies Smith E(3), Ribaudo

Proteome-Wide Genetic Study in East Asians and Europeans Identified Multiple Therapeutic Targets for Ischemic Stroke.

10. Stroke. 2025 Aug;56(8):2147-2158. doi: 10.1161/STROKEAHA.125.050982. Epub 2025 Apr 30. Proteome-Wide Genetic Study in East Asians and Europeans Identified Multiple Therapeutic Targets for Ischemic Stroke. Yao P(1), Mazidi M(1), Pozarickij A(1), Iona A(1)(2), Wright N(1), Lin K(1), Millwood

Single-dose tolerability and pharmacokinetics of leritrelvir in Chinese patients with hepatic impairment and healthy matched controls.

10. Antimicrob Agents Chemother. 2025 Feb 13;69(2):e0137724. doi: 10.1128/aac.01377-24. Epub 2024 Dec 17. Single-dose tolerability and pharmacokinetics of leritrelvir in Chinese patients with hepatic impairment and healthy matched controls. Li C(1), Mai J(1), Wu M(1), Zhang H(1), Li X(1), Li H(2

Pharmacokinetics and safety of GST-HG171, a novel 3CL protease inhibitor, in Chinese subjects with impaired and normal liver function.

50. Antimicrob Agents Chemother. 2024 Aug 7;68(8):e0053924. doi: 10.1128/aac.00539-24. Epub 2024 Jul 11. Pharmacokinetics and safety of GST-HG171, a novel 3CL protease inhibitor, in Chinese subjects with impaired and normal liver function. Zhou J(1), Zhang H(1), Chen H(1), Zhang G(2), Mao J(2),

[Pharmacological characteristics and clinical study results of ensitrelvir fumaric acid (XOCOVA(®) Tablets 125 ‍mg)].

15. Nihon Yakurigaku Zasshi. 2024;159(4):264-281. doi: 10.1254/fpj.24017. [Pharmacological characteristics and clinical study results of ensitrelvir fumaric acid (XOCOVA(®) Tablets 125 ‍mg)]. [Article in Japanese] Tsuge Y(1), Ariwa Y(2), Shibata K(2). Author information: (1)Clinical Development

Anticoronavirus activity of rhizome of Dryopteris crassirhizoma via multistage targeting of virus entry and viral proteases, Mpro and PLpro.

1. J Ethnopharmacol. 2024 Oct 28;333:118490. doi: 10.1016/j.jep.2024.118490. Epub 2024 Jun 25. Anticoronavirus activity of rhizome of Dryopteris crassirhizoma via multistage targeting of virus entry and viral proteases, Mpro and PLpro. Habib M(1), Jin YH(2), Kim Y(3), Min JS(4), Ha IJ(5), Lee SM

Efficacy and safety of sofosbuvir-velpatasvir and sofosbuvir-velpatasvir-voxilaprevir for hepatitis C in Korea: a Phase 3b study.

36. Korean J Intern Med. 2023 Jul;38(4):504-513. doi: 10.3904/kjim.2022.252. Epub 2023 Jun 30. Efficacy and safety of sofosbuvir-velpatasvir and sofosbuvir-velpatasvir-voxilaprevir for hepatitis C in Korea: a Phase 3b study. Heo J(1), Kim YJ(2), Lee SW(3), Lee YJ(4), Yoon KT(5), Byun KS(6), Jung

Evaluation of the Drug-Drug Interaction Potential of Ensitrelvir Fumaric Acid with Cytochrome P450 3A Substrates in Healthy Japanese Adults.

18. Clin Drug Investig. 2023 May;43(5):335-346. doi: 10.1007/s40261-023-01265-8. Epub 2023 May 12. Evaluation of the Drug-Drug Interaction Potential of Ensitrelvir Fumaric Acid with Cytochrome P450 3A Substrates in Healthy Japanese Adults. Shimizu R(1), Sonoyama T(2), Fukuhara T(3), Kuwata A(3),